INTRODUCTION
Natural menopause, defined as the cessation of menstruation, is retrospectively determined following 12 months of amenorrhea during the midlife period;
1 surgical menopause, on the other hand, is defined as cessation of menses because of removal of both ovaries, with or without removal of the uterus. 2 During menopause, between 55-75% of women will experience vasomotor symptoms (hot flashes) or other symptoms such as depression, mood swings, sleep disorders, vaginal dryness, and joint pain.
3 Approximately 25-30% of women will seek treatment from their healthcare provider for the adverse effects of menopause, 3 and many use hormone replacement therapy (HRT) for the treatment of menopausal symptoms. 4 Numerous studies have demonstrated the shortand long-term benefits of HRT; these include the relief of menopausal symptoms such as hot flashes and insomnia, 3, 4 and possible reductions in the risk of cardiovascular disease, osteoporosis, and Alzheimer's disease. [5] [6] [7] A significant number of women never seek treatment, or will refuse/discontinue HRT owing to the perceived risks, medical contraindications, or a general reluctance to use "unnatural" exogenous hormones. 8 The concern regarding HRT and breast cancer appears justified; a small but significant increase in breast cancer, coronary heart disease, and stroke was observed among long-term estrogen users. 9, 10 Many women are now actively seeking alternative approachesincluding botanical dietary supplements such as black cohosh-to manage their menopausal symptoms.
Black cohosh, known scientifically as Actaea racemosa L (syn. Cimicifuga racemosa (L) Nutt, Ranunculaceae), is a coarse perennial woodland herb with large compound leaves and a thick, knotted rhizome (root) system. 11 The plant is native to North America, with a distribution from southern Canada to Georgia. There are numerous common names for this plant, including black snakeroot, black root, bugbane, rattle root, rattle top, rattle squawroot, snake root, and rattleweed. 12 Black cohosh rhizomes and roots were routinely used as medicine by Native Americans (i.e., Penobscot, Winnebago, and Dakota) for the treatment of coughs, colds, constipation, fatigue, and rheumatism, as well as to increase breast milk production. 13, 14 In 1832, Dr. John King, an eclectic physician, began using a tincture of black cohosh rhizome for the treatment of pain and inflammation associated with endometriosis, rheumatism, neuralgia, and dysmenorrhea. 13, 14 From 1840 to 1946, a fluid extract of black cohosh was listed in the U.S. National Formulary. Currently, black cohosh products are marketed in the United States as herbal remedies for the treatment of menopausal symptoms and are regulated as dietary supplements.
STANDARDIZATION AND QUALITY ISSUES
The characteristic chemical constituents of the roots and rhizomes of black cohosh include cycloartenol-type triterpenoids, such as actein, 23-epi-27-deoxyactein, and cimicifugoside, as well as cinnamic acid derivatives (i.e., ferulic acid, isoferulic acid, and piscidic and fukiic acid esters) 12, 15 ( Figures 1 and 2) . Although the estrogenic isoflavone, formononetin (Figure 2 ), is reportedly a chemical constituent of black cohosh, its presence was not detected in alcoholic extracts of the root/ rhizome. 16, 17 Formononetin is a constituent of red clover ( Trifolium pratense ), and to a lesser extent, soybean ( Glycine max ); its presence in a black cohosh extract may have been due to improper taxonomic identification of the starting plant material or to adulteration with plant parts other than the roots and rhizomes.
Today, standardized extracts and other commercial products of black cohosh are prepared from the dried rhizomes and roots of the plant. 12 Remifemin® (SBC-R) is a commercially available black cohosh product that is a dried 40% isopropanol extract (although a 60% ethanol is also used as a solvent) of the roots and rhizomes. The extract is standardized to contain 1 mg of triterpenes (Figure 1 ) calculated as 27-deoxyactein (now known as 26-deoxyactein) per 20 mg of extract. This is the only commercial black cohosh extract to be tested clinically for safety and efficacy thus far.
REVIEW OF THE CLINICAL EVIDENCE
Prior to 1970, at least 14 studies were published regarding black cohash; these detailed case reports and clinical investigations of black cohosh for various gynecologic ailments. 12 Since 1982, at least 11 clinical trials have assessed the efficacy of a standardized formulation of black cohosh (40% isopropyl alcohol or a 60% ethanol extract of the roots and rhizomes, SBC-R, commercially known as Remifemin®) for the symptomatic treatment of climacteric symptoms such as anxiety, hot flushes, profuse sweating, insomnia, and vaginal atrophy. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Of the 11 trials, six were randomized controlled or comparison trials, [19] [20] [21] 23, 26, 27 and the other five were uncontrolled studies. 18, 22, 24, 25, 28 Many of the trials have methodological flaws, including lack of placebo groups, no randomization, lack of double blinding, small sample size, and usage of different doses.
Stoll conducted a 12-week randomized, doubleblind, placebo-controlled trial that compared the efficacy of a SBC-R extract with that of conjugated estrogens or placebo for the treatment of climacteric symptoms and vaginal atrophy. 23 Eighty women between the ages of 45-58 were treated with 8 mg per day of the extract (which corresponds to 48-140 mg of the dried herb), 0.625 mg per day of conjugated estrogens, or a placebo. Outcomes were measured using the Kupperman Index (KI) for climacteric symptoms, the Hamilton Anxiety Rating Scale (HAMA), and the vaginal maturity index. At the end of the 12-week treatment period, all groups showed improvements. In the group treated with black cohosh, however, a significant decrease in climacteric symptoms was observed by a reduction in the KI from 34 to 14 ( P Ͻ 0.001), which indicates an improvement in vasomotor symptoms. There was also a significant decrease in the HAMA ( P Ͻ 0.001), which indicates a reduction in anxiety, and a significant improvement in the proliferative status of the vaginal epithelium ( P Ͻ 0.01), which indicates a possible estrogenic effect. Minor adverse events were reported in the group that was treated with the extract, including headache, weight gain, mastalgia, and leg heaviness. The major criticism of this study was the lack of effect of the low-dose estrogen (0.625 mg), which was reported to be less effective than placebo. 23 A randomized comparison trial assessed the efficacy of black cohosh for the treatment of climacteric symptoms in 60 women under the age of 40 who had undergone a hysterectomy but retained one ovary. 20 The women were treated with estriol (1 mg/day), conjugated estrogens (1.25 mg/day), an estrogen-progesterone sequence therapy (2 mg estradiol and 1 mg norethindrone acetate), or the SBC-R extract (8 mg/day corresponding with 49-140 mg of dried herb) for six months. The results of each treatment were determined at 4, 8, 12, and 24 weeks, and outcomes were measured using a modified KI, as well as the serum concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH). The results showed a statistically significant decrease in climacteric symptoms in all treatment groups ( P Ͻ 0.01), as measured by reductions in a modified KI. Conjugated estrogens or estrogen-progesterone combinations appeared to be slightly more effective than the black cohosh extract; however, the difference between the three treatment groups was not statistically significant. Serum levels of LH and FSH did not change in any of the treatment groups. 20 The major flaw of this trial was the lack of a placebo group, and the lack of change in FSH or LH levels in those patients treated with estrogen or the estrogen/progesterone combination.
A controlled comparison trial, which involved 60 women between ages 45-60, compared the efficacy of the SBC-R extract with the efficacy of conjugated estrogens or diazepam for the treatment of climacteric symptoms. 26 The outcomes measured included a modified KI index comprised of the following symptoms: hot flashes, nocturnal sweating, nervousness, headache, and palpitations. Assessment of the vaginal epithelium proliferation was also performed. Psychological symptoms were measured using the HAMA and self-assessment depression scale (SDS). The patients were treated with 80 drops (1 mL equivalent to 1 mg) of a 60% ethanol extract of black cohosh, 0.625 mg conjugated estrogens, or 2 mg diazepam daily for a period of 12 weeks. Unfortunately, no placebo group was included. All three forms of therapy reduced the modified KI, HAMA, and SDS. A reduction in atrophic changes in the vaginal mucosa was also observed in the groups treated with black cohosh or conjugated estrogens. of Remifemin® in breast cancer survivors. 27 Eightyfive women, who were diagnosed with breast cancer and had completed their primary treatment (types of treatment not indicated), were randomly assigned to black cohosh or to a placebo, stratified on tamoxifen use. At baseline, patients completed a questionnaire about menopausal symptoms. In addition, before starting treatment, as well as at 30 and 60 days into treatment, the women kept a fourday hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. FSH and LH levels were measured in a subset of patients at the first and final visits. Of the 85 patients enrolled in the study (59 on tamoxifen, 26 not on tamoxifen), 42 (29 using tamoxifen) were assigned to treatment (40 mg of black cohosh extract/day) and 43 (30 using tamoxifen) were assigned to placebo; 69 completed all three hot flash diaries. Both the treatment and the placebo groups reported declines in number and intensity of hot flashes, but the differences between the groups were not statistically significant. The treatment/no tamoxifen group ( n ϭ 9) experienced a continued decline in hot flash intensity; however, owing to the small number of women in this group, this change was not statistically significant. Changes in blood levels of FSH and LH also did not differ between the two groups. The only symptom that showed a significant ( P ϭ 0.04) difference was sweating. 27 The major limitations of this study include the small sample size, the high dropout rate (18.8%), the short treatment period (two months), and the low dose of black cohosh (40 mg/day as opposed to 80 mg/day used in the other trials). In addition, because the mechanism of black cohosh is not understood, the confounding effects of tamoxifen, an estrogen agonist/antagonist, may have influenced the results.
A randomized, double-blind clinical trial involving 152 women with climacteric symptoms compared the effects of two different doses of Remifemin (40% isopropyl alcohol extract, corresponding to 39 mg drug vs. 127 mg drug/day) over three or six months. 21 A decrease in the KI (beginning value 31) was observed after two weeks in both treatment groups. Both dosage levels had similar therapeutic safety and efficacy. After six months of treatment, the number of responders (KI Յ 15) was approximately 90%. No effects on the levels of LH, FSH, sex hormone-binding globulin, prolactin, estradiol, or vaginal cytology were observed. 21 Unfortunately, no placebo or comparison drug were used in this investigation.
Whereas the value of uncontrolled trials is very limited owing to the high placebo response, some of the investigations did provide statistical analysis of the data, and are included for the sake of completeness. In an uncontrolled clinical trial involving 50 women with climacteric complaints, oral administration of a black cohosh extract (Remifemin®, 80 mg/day) reduced moderate symptoms to "requiring no therapy" after 12 weeks of treatment. 25 In another uncontrolled trial, 36 women with climacteric symptoms were treated with a 60% ethanol extract of black cohosh (80 mg/day) for 12 weeks. 18 A statistically significant ( P Ͻ 0.001) decrease in the average values of the KI was reported, and an increase in the Clinical Global Impressions scale was observed. 18 In an open study, 50 women with climacteric symptoms, who had previously been treated with intramuscular injections of estradiol valerate (4 mg) and prasteronenantate (200 mg, every for to six weeks), were alternatively treated with a SBC-R extract (80 mg/day for six months). 22 The therapeutic results were rated as "good" to "very good" in 41 of the patients. Twenty-eight patients (56%) required no further injections, 21 patients (44%) required one injection in six months, and one patient required two injections. The KI decreased to below 15 points ( P Ͻ 0.001), indicating alleviation of symptoms. 22 An open multicenter drug-monitoring study of 629 patients with meno- Figure 2 . Cinnamic acid derivatives such as ferulic acid are constituents of black cohosh rhizomes, whereas the isoflavone, formononetin, is not a constituent of black cohosh but rather is found in red clover.
pausal symptoms assessed the efficacy of SBC-R extract at a dose of 80 mg daily for eight weeks of treatment. 24 Symptoms such as hot flashes, profuse sweating, headache, vertigo, nervousness, and depression were improved in more than 80% of all cases after six to eight weeks of treatment with the extract. 24 Case reports with a total of 833 women have described the use of Remifemin® for the treatment of climacteric symptoms, as well as the treatment of menstrual disorders such as primary or secondary amenorrhea and premenstrual disorders. [29] [30] [31] [32] [33] Due to the limited value of such reports, the details are not described.
In addition to climacteric symptoms, one clinical trial specifically assessed the effect of a standardized extract of black cohosh on gonadotropin secretion. A placebo-controlled clinical trial involving 110 women with climacteric symptoms assessed the effect of the SBC-R extract on serum levels of LH and FSH. 19 The women were treated with the extract (8 mg/day) or a placebo for two months. Blood samples were taken after treatment and the concentrations of LH and FSH in the serum were determined by radioimmunoassay. Whereas a significant reduction in serum LH levels ( P Ͻ 0.05) was seen in the group receiving treatment compared with the group receiving placebo, no difference in serum FSH levels was observed between the treatment and placebo groups.
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MECHANISM OF ACTION
The mechanism by which black cohosh reduces hot flashes is not well understood, and there are conflicting reports in the literature with regard to its possible estrogenic effects. Data from clinical trials are contradictory. In one study, treatment with the SBC-R extract led to a significant reduction in LH levels as compared with placebo; however, the methodology of this study is questionable because baseline measurements were not performed. 19 In other clinical investigations, there was no effect observed on serum hormone concentrations in women treated with the SBC-R extract. 20, 23, 27 The effects of this extract on the proliferation of vaginal tissue or the endometrium are also contradictory. 21, 23 To date, in vitro and in vivo studies assessing the effects of black cohosh on estrogen receptor-positive breast cancer cell lines have shown mixed results. Treatment of human mammary carcinoma cells with Ͻ 2.5 g/mL of SBC-R did not enhance growth of the cells in vitro, whereas higher concentrations of the extract ( Ն 2.5 g/mL) caused a significant inhibition of cell proliferation. 34 Similar results were reported in an investigation that used an estrogen-dependent human mammary cancer cell line (MCF-7). 35 Conversely, one study using an undefined extract of black cohosh, at a concentration of 4.75 g/mL, significantly ( P Ͻ 0.01) enhanced the growth of MCF-7 cells in vitro. 36 The results of investigations assessing the estrogenic effects of black cohosh in female rats are also conflicting. In a report published in 1997, oral administration of an unspecified black cohosh extract to ovariectomized female rats daily for three weeks increased uterine weights. 37 Conversely, in a study published in 1996, intragastric or subcutaneous administration of a 50% ethanol extract of black cohosh (30, 300, or 3000 mg/kg) to immature mice for three days did not induce changes in uterus weight and vaginal smears. 38 These contradictory results may be explained by the differing length of treatment of the animals, age of the animals, and the different types of extracts and doses used in the investigations. Early reports from the 1980s suggested that formononetin, a phytoestrogen, was the active estrogenic constituent of black cohosh rhizomes. 39 However, a recent in-depth chemical analysis failed to find formononetin in any extract of black cohosh rhizomes. 40 Such discrepancies are illustrative of the fact that the use of undefined extracts of unauthenticated plant materials tend to confound the scientific literature.
The most recent investigations do not support an estrogen receptor-mediated mechanism of action for black cohosh. Data from work performed at the Center for Botanical Dietary Supplements Research at the University of Illinois at Chicago has shown that methanol extracts of black cohosh rhizomes (plants were authenticated by taxonomic specialists and DNA analysis) do not bind to purified ER␣ and ER␤, do not increase the activity of estrogen-dependent alkaline phosphatase in Ishikawa cells, and do not up-regulate the expression of the estrogen-sensitive pS2 (presenelin-2) or the progesterone receptor mRNA. 41 These data are supported by another recent study demonstrating that black cohosh extracts do not increase the proliferation of MCF-7 cancer cells or increase uterine weight after oral administration of the extract to female mice for four days. 42 In yet another study, treatment of breast cancer cells with the SBC-R extract did not stimulate cell proliferation, but instead prevented estradiolinduced cell proliferation (Ͼ1 g/mL) indicating anti-estrogenic effects. 43 Finally, a recent investigation of the SBC-R extract found no tumor-promoting effects in female rats with estrogen-dependent tumors. 44 Thus, the most recently published studies do not support an estrogenic mechanism for black cohosh, and alternative mechanisms of action are currently under investigation.
CONCLUSION
Black cohosh (Cimicifuga racemosa) has been used as an herbal remedy by women for more than 100 years and is currently advocated as an alternative therapy for menopausal symptoms. A review of the clinical trial data suggests that treatment with a standardized black cohosh extract may be of some benefit for the relief of hot flashes. It is important to remember that all the trials cited in this review used a standardized black cohosh extract (Remifemin®) at a dose corresponding to 40-80 mg daily. As with many other botanicals, however, the methodology used in all the published clinical trials is flawed, and even the most recent trial had significant limitations. Data from longer, more rigorous clinical trials performed with well-defined extracts of botanically authenticated plant materials are needed. 45 There are currently two randomized, double-blind, placebo-controlled trials underway, both of which are funded by the National Institutes of Health. One study is being performed at Columbia University in New York, and the other at the Center for Botanical Dietary Supplements Research in Women's Health at the University of Illinois at Chicago.
The most recent investigations do not support an estrogen-receptor mediated theory as a plausible mechanism of action of black cohash. Alternate mechanisms of action have been proposed, such as a dopaminergic or serotoneric effects, and pharmacologic investigations in these areas are currently underway. 
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